3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia
2
Recurrence
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
COVID-19
1
Interventions
cilgavimab and tixagevimab drug combination
2
Standard of Care
2
Specimen Handling
2
Practice Guidelines as Topic
2
CVnCoV COVID-19 vaccine
2
COH04S1 COVID-19 vaccine
2
BNT162 Vaccine
2
sotrovimab
1
ogalvibart
1
crexavibart
1
bemcentinib
1
Therapeutics
1
Surveys and Questionnaires
1
Hydroxychloroquine
1
HuMax-IL8
1
Data Collection
1
COVID-19 Vaccines
1
Blood Specimen Collection
1
Azithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
COVID-19
×
Hydroxychloroquine
×
Other hematologic neoplasm
×
Clear all
NCT04392128
2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2
Withdrawn